Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumon...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Scientific Communications International
2021
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/22454/1/22454.pdf |
| _version_ | 1824416532583677952 |
|---|---|
| author | Pérez Alba, Eduardo Nuzzolo Shihadeh, Laura Marina Aguirre García, Gloria Mayela Espinosa Mora, Jaime Eugenio Lecona García, Juan Diego Flores Pérez, Rómulo Omar Mendoza Garza, Marisela Camacho Ortiz, Adrián |
| author_facet | Pérez Alba, Eduardo Nuzzolo Shihadeh, Laura Marina Aguirre García, Gloria Mayela Espinosa Mora, Jaime Eugenio Lecona García, Juan Diego Flores Pérez, Rómulo Omar Mendoza Garza, Marisela Camacho Ortiz, Adrián |
| author_sort | Pérez Alba, Eduardo |
| collection | Repositorio Institucional |
| description | Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy.
Methodology: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) thatwere treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates.
Results: A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD � 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/ 197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P Z <.05). There was no difference in hospital acquired infections between both groups. |
| format | Article |
| id | eprints-22454 |
| institution | UANL |
| language | Spanish / Castilian |
| publishDate | 2021 |
| publisher | Scientific Communications International |
| record_format | eprints |
| spelling | eprints-224542024-03-04T17:28:49Z http://eprints.uanl.mx/22454/ Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis Pérez Alba, Eduardo Nuzzolo Shihadeh, Laura Marina Aguirre García, Gloria Mayela Espinosa Mora, Jaime Eugenio Lecona García, Juan Diego Flores Pérez, Rómulo Omar Mendoza Garza, Marisela Camacho Ortiz, Adrián QR Microbiología Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) thatwere treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates. Results: A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD � 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/ 197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P Z <.05). There was no difference in hospital acquired infections between both groups. Scientific Communications International 2021 Article PeerReviewed text es cc_by_nc_nd http://eprints.uanl.mx/22454/1/22454.pdf http://eprints.uanl.mx/22454/1.haspreviewThumbnailVersion/22454.pdf Pérez Alba, Eduardo y Nuzzolo Shihadeh, Laura Marina y Aguirre García, Gloria Mayela y Espinosa Mora, Jaime Eugenio y Lecona García, Juan Diego y Flores Pérez, Rómulo Omar y Mendoza Garza, Marisela y Camacho Ortiz, Adrián (2021) Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. Journal of Microbiology, Immunology and Infection, 54 (5). pp. 787-793. ISSN 16841182 http://doi.org/10.1016/j.jmii.2021.05.009 doi:10.1016/j.jmii.2021.05.009 |
| spellingShingle | QR Microbiología Pérez Alba, Eduardo Nuzzolo Shihadeh, Laura Marina Aguirre García, Gloria Mayela Espinosa Mora, Jaime Eugenio Lecona García, Juan Diego Flores Pérez, Rómulo Omar Mendoza Garza, Marisela Camacho Ortiz, Adrián Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| title_full | Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| title_fullStr | Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| title_full_unstemmed | Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| title_short | Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis |
| title_sort | baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe covid 19 pneumonia a retrospective analysis |
| topic | QR Microbiología |
| url | http://eprints.uanl.mx/22454/1/22454.pdf |
| work_keys_str_mv | AT perezalbaeduardo baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT nuzzoloshihadehlauramarina baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT aguirregarciagloriamayela baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT espinosamorajaimeeugenio baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT leconagarciajuandiego baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT floresperezromuloomar baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT mendozagarzamarisela baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis AT camachoortizadrian baricitinibplusdexamethasonecomparedtodexamethasoneforthetreatmentofseverecovid19pneumoniaaretrospectiveanalysis |